Reuters logo
2 年前
BRIEF-Galapagos JAK1 inhibitor filgotinib meets key efficacy endpoints after 24 weeks
2015年7月30日 / 早上6点48分 / 2 年前

BRIEF-Galapagos JAK1 inhibitor filgotinib meets key efficacy endpoints after 24 weeks

July 30 (Reuters) - Galapagos NV :

* Said on Wednesday its JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39 pct, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study

* Up to 64 pct of patients achieved DAS28(CRP) remission or low disease state, all doses and regimens statistically significant at week 24

* Safety profile consistent with data at week 12: increased hemoglobin, higher increases in HDL than LDL, no change to lymphocyte counts

Source text for Eikon:

Further company coverage:

Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below